Login to Your Account



Signs $200M Pact with Novartis

Merus Gets $30M for 'Simple' Antibody Cocktail Platform

By Cormac Sheridan


Wednesday, February 3, 2010
Merus BV, which is developing a novel antibody platform, raised €21.7 million (US$30.3 million) in a Series B round and entered a license option agreement with Novartis AG potentially worth more than $200 million in up-front and milestone payments. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription